Chimerix shares remain undervalued, says Cowen Cowen believes shares of Chimerix remain undervalued following its dinner management. The firm remains confident its SUPPRESS trial for brincidofovir will succeed in 2015 and expects other opportunities for the drug to materialize in 2014. Shares are Outperform rated with a $27 price target.
Keryx initiated with a Sell, $1.50 price target at Citi Citi analyst Yigal Nochomovitz started shares of Keryx Biopharmaceuticals (KERX) with a Sell rating and $1.50 price target. The stock closed yesterday up 18c to $6.03. Nochomovitz expects the Auryxia launch and long-term sales trends to "materially underperform" consensus expectations. Auryxia is a phosphate binder used for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis. Nochomovitz estimates Auryxia has peak U.S. sales potential of $57M, well below the consensus estimate of $485M. He named Chimerix (CMRX) his top pick in the small- and mid-cap biotech space. The analyst initiated the name this morning with a Buy rating and $80 price target.
Chimerix initiated with a Buy at Citi Citi analyst Yigal Nochomovitz started shares of Chimerix with a Buy rating and $80 price target. The analyst has "high conviction" that the company's brincidofovir will "transform" the lives of transplant patients and the standard of care in multiple transplant settings. Nochomovitz also calls a takeout thesis "not outrageous." Chimerix is the analyst's top pick in the small- and mid-cap biotech space.